Thalia Therapeutics plc
THAT · AIM · Health Care · mcap £11m · 0.6p
Northern Standard Limited
29 Jul · 1 notice
16.7% → 18.0%
share price at the notices 0.7p · now 0.6p
29 Jul 2026
NLC Ventures Netherlands B.V.
21 Jul · 1 notice
0.0% → 14.5%
share price at the notices 0.7p · now 0.6p
21 Jul 2026
NLC Health Impact Fund Coöperatief U.A.
21 Jul · 1 notice
0.0% → 3.9%
share price at the notices 0.7p · now 0.6p
21 Jul 2026
Directors and managers
Last 12 months: no purchases with their own money · no market sales · 1 other transaction (awards, vesting, tax sales, fee and dividend shares)
Own-money trades (bought or sold in the market) say most about what insiders think. Awards, vesting, shares sold to cover tax, fees and dividends taken in shares are part of pay.
| Date | Person | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| 23 Jul 26 | 1. David Solomon (Chief Executive) 2. Chris Britten (Non-Executive Chair) 3. Luke Cairns (Executive Director) 4. Alastair Smith (Non-Executive Director) 5. Michael Palfreyman (Non-Executive Director)See 1 a) | Award | 50,000,000 | 0.6p | £300k |
No director bought or sold shares in the market in this period – show all 1 transactions.
Company filings. Not investment advice.